Leerink Partnrs Reiterates Outperform Rating for Morphic (NASDAQ:MORF)

Leerink Partnrs reaffirmed their outperform rating on shares of Morphic (NASDAQ:MORF – Free Report) in a report issued on Monday, PriceTargets.com reports. Leerink Partnrs also issued estimates for Morphic’s Q3 2023 earnings at ($0.82) EPS, Q4 2023 earnings at ($0.85) EPS, FY2023 earnings at ($3.48) EPS, FY2024 earnings at ($4.18) EPS, FY2025 earnings at ($4.45) […]

Related Keywords

,Marc Schegerin ,Leerink Partnrs ,Praveenp Tipirneni ,Stifel Nicolaus ,Group One Trading ,Metlife Investment Management ,Jpmorgan Chase Co ,Securities Exchange Commission ,Nasdaq ,Berenberg Bank ,Morphic Holding Inc ,York Mellon Corp ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,New York Mellon Corp ,Life Investment Management ,Rhumbline Advisers ,Morphic Daily ,Amorphic ,Nasdaq Morf ,Smorf ,Medical ,Reiterated Rating ,